Anxiety and Reward Interaction and Prediction of Outcomes in Anorexia Nervosa

Anxiety Clinical Trial

Official title:

Anxiety and Reward Interaction and Prediction of Outcomes in Anorexia Nervosa

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02948452
• Other study ID #: 1R01MH105662-01A1
• Secondary ID: 1R01MH105662-01A
• Status: Completed
• Start date: November 2015
• Est. completion date: June 30, 2021

Study information

• Verified date: May 2023
• Source: University of California, Los Angeles
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study is designed to understand responsiveness to reward in adolescents with restricting-type anorexia nervosa compared with non-clinical controls, and how it is affected by potential-threat perception.

Description:

The objective of this study is to understand the effects of anxiety on reward responsiveness in adolescents with anorexia nervosa (AN), and how this interaction predicts behavioral outcome subsequent to intensive treatment. Investigators plan to test, for the first time, how acute activation of threat related emotional circuitry reciprocally alters reward circuit activity, and to what degree this modulation predicts post treatment relapse. The severity of AN, its resistance to intervention, potential for quick return of illness, risk for long-term chronicity, and premature death, are well appreciated. Various forms of intensive treatment may succeed in at least partial weight restoration, yet early relapse is unusually high. The appearance early in life of prodromal anxiety phenotypes in individuals who subsequently develop AN is well documented and nearly universal. Anxiety proneness in concert with rigid self-discipline may therefore be predisposing substrates for sudden morbid apprehension about weight gain, and may contribute to subsequent behaviors including vigilant scrutiny of body size and shape and inflexible cognitive patterns regarding food and eating. In parallel, persons with restricting-type AN typically exhibit unease and reticence when exposed to novel, high reward environments. Most studies have found low fun-seeking, low novelty seeking, and reduced reward responsiveness in those with AN. In line with these observations, functional magnetic resonance imaging (fMRI) studies demonstrate aberrant reward sensitivity and reward circuit activation. However the interaction of anxiety and reward circuits has never been interrogated. There is substantial evidence of distinct yet overlapping neural systems mediating approach/reward and avoidance/anxiety, which are integrated in balancing and switching between behaviors related to the predominant valence state. Thus investigators posit that high degrees of reactivity of cortico-limbic circuits underlying anxiety may contribute mechanistically and functionally to diminished initial responsiveness to reward stimuli. This may translate clinically to lower motivation to engage in outpatient treatment - in effect, a lower drive to change behaviors and thought patterns necessary for maintaining gains or improving, based on expectancy of benefits of future outcome. The dynamic interaction between reward and anxiety systems in AN, and how dysregulation of connectivity within and between these systems mediates behavioral outcomes, has not previously been tested. Investigators will investigate this interaction using sequential fMRI paradigms and novel integrated functional-by-structural connectivity in individuals who have completed standard treatment on an eating disorder unit. Investigators will then investigate how this neural circuitry may predict degree of relapse during the subsequent 6 months.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 66
• Est. completion date: June 30, 2021
• Est. primary completion date: April 30, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 12 Years to 19 Years

Eligibility

Inclusion criteria for AN participants:

• Clinical diagnosis of Anorexia Nervosa, Restricting Type within the previous 6 months, (except for the amenorrhea criteria)

• completed treatment in an inpatient, residential, or partial hospitalization program (2-5 times/week) consisting of psychotherapy and dietary monitoring, within the previous 3 weeks

• May be unmedicated, or be taking a serotonin reuptake inhibitor medication at a stable dose for at least 8 weeks at the time of enrollment.

Exclusion criteria for AN participants:

• lifetime Axis I bipolar disorder, lifetime psychotic disorders, lifetime attention deficit hyperactivity disorder, or current post-traumatic stress disorder.

• current substance abuse or dependence, including nicotine

• pathological gambling, as assessed with the South Oaks Gambling Screen

• current neurological disorder

• pregnancy

• current major medical disorders that may affect cerebral metabolism such as diabetes or thyroid disorders

• current risk of suicide with a plan and intent

• a Children's Depression Rating Scale Revised (CDRS-R) score >75 or major depressive disorder with psychotic features

• ferromagnetic metal implantations or devices (electronic implants or devices, infusion pumps, aneurysm clips, metal fragments or foreign bodies, metal prostheses, joints, rods or plates)

• adjusted BMI = 25 (overweight)

• visual acuity worse than 20/35 for each eye as determined by Snellen close vision chart. Acuity may be met with corrective lenses.

Inclusion criteria for controls:

• non-clinical females who score at least 1 standard deviation higher than population norms on the Depression Anxiety Stress Scale (DASS-21)

Exclusion criteria for controls:

• any Axis I disorder

• any psychiatric medication.

• - current substance abuse or dependence, including nicotine

• pathological gambling, as assessed with the South Oaks Gambling Screen

• current neurological disorder

• pregnancy

• current major medical disorders that may affect cerebral metabolism such as diabetes or thyroid disorders

• current risk of suicide with a plan and intent

• a Children's Depression Rating Scale Revised (CDRS-R) score >75 or major depressive disorder with psychotic features

• ferromagnetic metal implantations or devices (electronic implants or devices, infusion pumps, aneurysm clips, metal fragments or foreign bodies, metal prostheses, joints, rods or plates)

• adjusted BMI = 25 (overweight)

• visual acuity worse than 20/35 for each eye as determined by Snellen close vision chart. Acuity may be met with corrective lenses.

Related Conditions & MeSH terms

• Anorexia
• Anorexia Nervosa
• Anorexia Nervosa, Restricting Type
• Anxiety
• Anxiety Disorders

Intervention

Other:
• fMRI
fMRI: reward task, anxiety provocation

Locations

Country	Name	City	State
United States	UCLA	Los Angeles	California

Sponsors (2)

Lead Sponsor	Collaborator
University of California, Los Angeles	National Institute of Mental Health (NIMH)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Blood oxygen level dependent (BOLD) percentage signal change as measured by fMRI in anxiety and reward brain regions of interest	Mean BOLD percentage signal change between anxiety and control conditions will be compared across anorexia nervosa and comparison participants during the reward task	within 3 weeks of discharge from an intensive treatment program
Secondary	Body Mass Index (BMI) in kg/meter squared monthly for 6 months	Trajectory of BMI over 6 months after intensive treatment will be analyzed	6 months
Secondary	Eating disorder symptoms	Eating Disorder Examination (EDE)	beginning of study and at 6 months